Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 47


Safety and Efficacy of a Novel Microbial Lipase in Patients with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis: A Randomized Controlled Clinical Trial.

Heubi JE, Schaeffer D, Ahrens RC, Sollo N, Strausbaugh S, Graff G, Jain R, Witte S, Forssmann K.

J Pediatr. 2016 Sep;176:156-161.e1. doi: 10.1016/j.jpeds.2016.05.049. Epub 2016 Jun 11.


Bioassay of salmeterol in children using methacholine challenge with impulse oscillometry.

Mondal P, Baumstein S, Prabhakaran S, Abu-Hasan M, Zeng Y, Singh S, Wang K, Ahrens RC, Hendeles L.

Pediatr Pulmonol. 2016 Jun;51(6):570-5. doi: 10.1002/ppul.23345. Epub 2015 Nov 17.


Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis.

Chmiel JF, Konstan MW, Accurso FJ, Lymp J, Mayer-Hamblett N, VanDevanter DR, Rose LM, Ramsey BW; Assessment of Induced Sputum in Cystic Fibrosis Study Group.

J Cyst Fibros. 2015 Nov;14(6):720-6. doi: 10.1016/j.jcf.2015.03.007. Epub 2015 Apr 11.


Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis.

Mayer-Hamblett N, Rosenfeld M, Treggiari MM, Konstan MW, Retsch-Bogart G, Morgan W, Wagener J, Gibson RL, Khan U, Emerson J, Thompson V, Elkin EP, Ramsey BW; EPIC; ESCF Investigators.

Pediatr Pulmonol. 2013 Oct;48(10):943-53. doi: 10.1002/ppul.22693. Epub 2013 Jul 2.


Long-term intersession variability for single-breath diffusing capacity.

Hegewald MJ, Jensen RL, Teeter JG, Wise RA, Riese RJ, England RD, Ahrens RC, Crapo RO, MacIntyre NR.

Respiration. 2012;84(5):377-84. doi: 10.1159/000334699. Epub 2011 Dec 31.


Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.

Mayer-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch-Bogart G, Treggiari MM, Burns JL, Khan U, Ramsey BW; EPIC Investigators.

Pediatr Pulmonol. 2012 Feb;47(2):125-34. doi: 10.1002/ppul.21525. Epub 2011 Aug 9.


Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort.

Rosenfeld M, Emerson J, McNamara S, Joubran K, Retsch-Bogart G, Graff GR, Gutierrez HH, Kanga JF, Lahiri T, Noyes B, Ramsey B, Ren CL, Schechter M, Morgan W, Gibson RL; EPIC Study Group Participating Clinical Sites.

Pediatr Pulmonol. 2010 Sep;45(9):934-44. doi: 10.1002/ppul.21279.


Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report.

Adams WP, Ahrens RC, Chen ML, Christopher D, Chowdhury BA, Conner DP, Dalby R, Fitzgerald K, Hendeles L, Hickey AJ, Hochhaus G, Laube BL, Lucas P, Lee SL, Lyapustina S, Li B, O'Connor D, Parikh N, Parkins DA, Peri P, Pitcairn GR, Riebe M, Roy P, Shah T, Singh GJ, Sharp SS, Suman JD, Weda M, Woodcock J, Yu L.

J Aerosol Med Pulm Drug Deliv. 2010 Feb;23(1):1-29. doi: 10.1089/jamp.2009.0803.


Genetic modifiers of liver disease in cystic fibrosis.

Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M Jr, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemková D, Hannah WB, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm ML, Wright FA, Lange EM, Durie PR, Knowles MR; Gene Modifier Study Group.

JAMA. 2009 Sep 9;302(10):1076-83. doi: 10.1001/jama.2009.1295.


Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.

Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW; EPIC Study Group.

Contemp Clin Trials. 2009 May;30(3):256-68. doi: 10.1016/j.cct.2009.01.003. Epub 2009 Jan 15.


Intersession variability in single-breath diffusing capacity in diabetics without overt lung disease.

Drummond MB, Schwartz PF, Duggan WT, Teeter JG, Riese RJ, Ahrens RC, Crapo RO, England RD, Macintyre NR, Jensen RL, Wise RA.

Am J Respir Crit Care Med. 2008 Aug 1;178(3):225-32. doi: 10.1164/rccm.200801-090OC. Epub 2008 May 8.


Standardization of the single-breath diffusing capacity in a multicenter clinical trial.

Wise RA, Teeter JG, Jensen RL, England RD, Schwartz PF, Giles DR, Ahrens RC, MacIntyre NR, Riese RJ, Crapo RO.

Chest. 2007 Oct;132(4):1191-7. Epub 2007 Sep 21.


The role of the MDI and DPI in pediatric patients: "Children are not just miniature adults".

Ahrens RC.

Respir Care. 2005 Oct;50(10):1323-8; discussion 1328-30. Review.


Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology.

Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, Smaldone GC, Guyatt G; American College of Chest Physicians; American College of Asthma, Allergy, and Immunology.

Chest. 2005 Jan;127(1):335-71. Review.


Levalbuterol has not been established to have therapeutic advantage over racemic albuterol.

Asmus MJ, Hendeles L, Weinberger M, Ahrens RC, Bisgaard H, Lötvall J, O'Byrne PM, Cockcroft DW.

J Allergy Clin Immunol. 2002 Aug;110(2):325; author reply 325-8. No abstract available.


The long and short isoforms of Ret function as independent signaling complexes.

Tsui-Pierchala BA, Ahrens RC, Crowder RJ, Milbrandt J, Johnson EM Jr.

J Biol Chem. 2002 Sep 13;277(37):34618-25. Epub 2002 Jun 28.


Tobramycin as a pharmacologic tracer to compare airway deposition from nebulizers.

Asmus MJ, Stewart BA, Milavetz G, Teresi ME, Han SH, Wang D, Ahrens RC.

Pharmacotherapy. 2002 May;22(5):557-63.


Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis.

Ahrens RC, Standaert TA, Launspach J, Han SH, Teresi ME, Aitken ML, Kelley TJ, Hilliard KA, Milgram LJ, Konstan MW, Weatherly MR, McCarty NA.

Pediatr Pulmonol. 2002 Feb;33(2):142-50.


Supplemental Content

Loading ...
Support Center